Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan Hausler

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Medrxiv : the Preprint Server for Health Sciences|August 20, 2025
Pathogenic germline variants in a racially diverse real-world cohort of prostate cancer patientsTaylor B Crawford, Maliha Tayeb, Emanuel Barrett, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 2, 2026
Pathogenic Germline Variants in a Racially Diverse Real-World Cohort of Patients With Prostate CancerTaylor B Crawford, Maliha Tayeb, Emanuel Barrett, et al.
Medrxiv : the Preprint Server for Health Sciences|February 7, 2023
Germline pathogenic variants in 786 neuroblastoma patientsJung Kim, Zalman Vaksman, Laura E Egolf, et al.
Journal of the National Cancer Institute|September 9, 2023
Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survivalJung Kim, Zalman Vaksman, Laura E Egolf, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Germline pathogenic variation impacts somatic alterations and patient outcomes in pediatric CNS tumorsRyan J Corbett, Rebecca S Kaufman, Shelly W McQuaid, et al.
Nature Communications|November 21, 2025
Germline pathogenic variation impacts somatic alterations and patient outcomes in pediatric central nervous system tumorsRyan J Corbett, Rebecca S Kaufman, Shelly W McQuaid, et al.
Leukemia|July 9, 2025
Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress responseSarah J Skuli, A'ishah Bakayoko, Marisa Kruidenier, et al.
European Urology|December 5, 2021
Inherited TP53 Variants and Risk of Prostate CancerKara N Maxwell, Heather H Cheng, Jacquelyn Powers, et al.
Cancer Research|July 18, 2020
A Rare <i>TP53</i> Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple CancersJacquelyn Powers, Emilia M Pinto, Thibaut Barnoud, et al.
The Journal of Clinical Investigation|April 3, 2025
ATM-dependent DNA damage response constrains cell growth and drives clonal hematopoiesis in telomere biology disordersChristopher M Sande, Stone Chen, Dana V Mitchell, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Medrxiv : the Preprint Server for Health Sciences|August 20, 2025
Pathogenic germline variants in a racially diverse real-world cohort of prostate cancer patientsTaylor B Crawford, Maliha Tayeb, Emanuel Barrett, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 2, 2026
Pathogenic Germline Variants in a Racially Diverse Real-World Cohort of Patients With Prostate CancerTaylor B Crawford, Maliha Tayeb, Emanuel Barrett, et al.
Medrxiv : the Preprint Server for Health Sciences|February 7, 2023
Germline pathogenic variants in 786 neuroblastoma patientsJung Kim, Zalman Vaksman, Laura E Egolf, et al.
Journal of the National Cancer Institute|September 9, 2023
Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survivalJung Kim, Zalman Vaksman, Laura E Egolf, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Germline pathogenic variation impacts somatic alterations and patient outcomes in pediatric CNS tumorsRyan J Corbett, Rebecca S Kaufman, Shelly W McQuaid, et al.
Nature Communications|November 21, 2025
Germline pathogenic variation impacts somatic alterations and patient outcomes in pediatric central nervous system tumorsRyan J Corbett, Rebecca S Kaufman, Shelly W McQuaid, et al.
Leukemia|July 9, 2025
Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress responseSarah J Skuli, A'ishah Bakayoko, Marisa Kruidenier, et al.
European Urology|December 5, 2021
Inherited TP53 Variants and Risk of Prostate CancerKara N Maxwell, Heather H Cheng, Jacquelyn Powers, et al.
Cancer Research|July 18, 2020
A Rare <i>TP53</i> Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple CancersJacquelyn Powers, Emilia M Pinto, Thibaut Barnoud, et al.
The Journal of Clinical Investigation|April 3, 2025
ATM-dependent DNA damage response constrains cell growth and drives clonal hematopoiesis in telomere biology disordersChristopher M Sande, Stone Chen, Dana V Mitchell, et al.
Pageof 3